Vinge advised Apotea on the deal. Apotea AB (publ) completed its listing on Nasdaq Stockholm. The offering price was SEK 58 per ordinary share, corresponding to a...
You must be a Standard 1 Year member to access this content.
Vinge advised Xspray Pharma on the deal. Xspray Pharma AB (publ) completed a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135...
You must be a Standard 1 Year member to access this content.
Vinge assisted Priveq on the deal. Priveq, a leading Nordic lower mid-market growth and buyout investor, has closed its seventh fund, Priveq Investment VII, at SEK...
You must be a Standard 1 Year member to access this content.
Vinge advised Tobii AB on the offering. Tobii AB (publ) finalized its rights issuance of ordinary shares which will provide Tobii with issue proceeds of approximately...
You must be a Standard 1 Year member to access this content.
Vinge advised Cell Impact AB on the deal. Cell Impact AB (publ) completed a rights issuance which will provide Cell Impact with issue proceeds of SEK 129...
You must be a Standard 1 Year member to access this content.
